Abstract:Objective: 22q11.2 deletion syndrome (22q11.2 DS) is the most common chromosomal microdeletion disorder. Associated problems in 22q11.2 DS may include cardiac abnormalities, immune dysfunction, facial dysmorphism, with endocrine, genitourinary and gastrointestinal problems, and developmental delay. The aim of this study was to evaluate and present all endocrinological findings of patients with 22q11.2 DS from a single center. Methods: All participants had confirmed 22q11.2 DS by fluorescence in situ hybridization with hypoparathyroidism. Data were retrieved by retrospective review of patient records. Results: A total of 17 patients were reviewed. On physical examination, all patients had similar dysmorphic features. The median age at diagnosis was 45 days (1 day-13 years). Most cases (64.7%, 11/17) were diagnosed with hypoparathyroidism incidentally after routine tests. At the time of diagnosis, mean calcium was 7.04±0.80 mg/dL, phosphorus was 6.2±1.1 mg/dL, and median parathyroid hormone (PTH) was 11.5 (3.7-47.6) ng/L. Transient hypoparathyroidism was detected in five cases (29.4%). There was no significant difference between patients with permanent or transient hypoparathyroidism regarding gender, age at diagnosis, calcium, phosphorus, and PTH levels. However, vitamin D levels were significantly lower in the transient group (p=0.036). During follow-up, short stature, obesity, and type 2 diabetes mellitus were absent. Thyroid autoantibodies were detected in two patients with normal thyroid function tests. Despite there being no pathological short stature, final stature was shorter than the general population (mean height standard deviation score: -0.94±0.83). Conclusion: Hypocalcemia may be detected during acute illness in some cases where hypocalcemia appears at later ages. There was no significant difference between permanent and transient hypoparathyroidism cases in terms of PTH level. Recognition of the more specific facial findings is important to trigger investigation of genetic variants, additional anomalies, and for follow-up.

22q11.2 Deletion Syndrome Causes a Thymus Hypoplasia Corrected by Mesenchymal Cell Replacement

Thymus Tissue Regeneration in 22q11.2ds Mouse Models (digeorge) Using Mesenchymal Cell Replacement or Vasodilators

Mesenchymal Cell Replacement Corrects Thymic Hypoplasia in Murine Models of 22q11.2 Deletion Syndrome

Immunologic defects in 22q11.2 deletion syndrome

Enlarged cavum septum pellucidum and small thymus as markers for 22q11.2 deletion syndrome

Primary and secondary defects of the thymus

Characterization of Human FOXN1 Mutations Uncovers both Loss- and Gain-of-Function Outcomes

Growth characteristics and endocrine abnormalities in 22q11.2 deletion syndrome

Increased Levels of Interferon-Inducible Protein 10 (IP-10) in 22q11.2 Deletion Syndrome

Congenital Athymia: Genetic Etiologies, Clinical Manifestations, Diagnosis, and Treatment

An Endocrinological Perspective on 22q11.2 Deletion Syndrome: A Single-center Experience

Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants

Thymic Atrophy and Immune Dysregulation in Infants with Complex Congenital Heart Disease

Molecular genetics of 22q11.2 deletion syndrome

Consequences of 22q11.2 Microdeletion on the Genome, Individual and Population Levels

Small Deletions of SATB2 Cause Some of the Clinical Features of the 2q33.1 Microdeletion Syndrome

Neonatal Levels of T-cell Receptor Excision Circles (TREC) in Patients with 22q11.2 Deletion Syndrome and Later Disease Features

Analysis of the Clinical Phenotype in 20 Children with 22q11.2 Deletion Syndrome

The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)

SLC25A1 Regulates Placental Development to Ensure Embryonic Heart Morphogenesis

haploinsufficiency leads to primate-specific RNA dysregulation and pluripotency defects